Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Non Operating Income (2021 - 2025)

Historic Non Operating Income for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to $3.4 million.

  • Prime Medicine's Non Operating Income rose 9784.13% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year decrease of 588.15%. This contributed to the annual value of $6.6 million for FY2024, which is 321.32% up from last year.
  • Latest data reveals that Prime Medicine reported Non Operating Income of $3.4 million as of Q3 2025, which was up 9784.13% from $786000.0 recorded in Q2 2025.
  • Over the past 5 years, Prime Medicine's Non Operating Income peaked at $3.4 million during Q3 2025, and registered a low of -$8.4 million during Q3 2021.
  • For the 5-year period, Prime Medicine's Non Operating Income averaged around $194764.7, with its median value being $786000.0 (2025).
  • In the last 5 years, Prime Medicine's Non Operating Income soared by 40651.34% in 2023 and then plummeted by 9273.17% in 2024.
  • Quarter analysis of 5 years shows Prime Medicine's Non Operating Income stood at -$1.5 million in 2021, then surged by 46.15% to -$783000.0 in 2022, then soared by 406.51% to $2.4 million in 2023, then dropped by 18.92% to $1.9 million in 2024, then surged by 74.25% to $3.4 million in 2025.
  • Its last three reported values are $3.4 million in Q3 2025, $786000.0 for Q2 2025, and $502000.0 during Q1 2025.